Health2 sources
FDA Approves Cemdisiran for Generalized Myasthenia Gravis
- The FDA approved cemdisiran (Livsayis) for treating generalized myasthenia gravis in adults.
- Cemdisiran is a subcutaneous small interfering RNA (siRNA) therapy.
- The drug is specifically for adults who are anti-acetylcholine receptor (AChR) antibody-positive.
- Regeneron announced the approval of cemdisiran for this condition.
- The approval was reported by both MedPage Today and Reuters.